Table 5 Trials of dapagliflozin in patients with type 1 diabetes mellitus currently registered on ClinicalTrials.gov

NCT02325206

I (Recruiting)

Randomized, placebo controlled, crossover

10 mg (single dose)

Safety and pharmacokinetics; degree of insulin dose reduction after 24-h

NCT01498185^a

II (Completed)

Randomized, double-blind, placebo controlled

1, 2.5, 5, 10 mg × 14 days

Safety, change from baseline mean plasma glucose, pharmacokinetics and pharmacodynamics

NCT02268214

III (Recruiting)

Randomized, double blind, placebo controlled

5 or 10 mg × 52 weeks

Efficacy (change in HbA_1c at week 24; change from baseline insulin dose, metabolic parameters.

NCT02211742

IV (Recruiting)

Randomized, double-blind, crossover

10 mg × 3 days

Effect of dapagliflozin on fasting glucose homeostasis and postprandial glucose excursions in male patients